Screening will save newborn lives: A case for the introduction of routine screening for group B Streptococcus in late pregnancy.
Foreword

Life-threatening group B Strep infections in newborn babies can usually be prevented. A simple and inexpensive test in the later stages of pregnancy can detect the bacteria, allowing treatment to be given to the mother during labour so preventing infection in the newborn baby. I’d like to see every pregnant woman in the UK offered a sensitive test for GBS on the NHS – this test is a routine part of antenatal care in many countries including France, Canada, Spain and the USA.

This report makes the simple case that the current system of only treating women identified through ‘risk factors’ is ineffective. While the number of GBS infections in newborn babies has risen in the UK, it has fallen dramatically in countries where routine screening has been introduced.

Dr Chris Steele MBE

During 2012, the UK National Screening Committee looked at the evidence published since 2008 regarding the introduction of routine testing for group B Strep for all pregnant women, deciding against its introduction at the end of the year. This decision was devastating for GBSS and all the parents, health professionals and others who have dedicated many hours to making the case that routine antenatal testing for group B Strep can save lives and reduce the risk of long term disability by preventing these devastating infections. In the UK, the incidence of GBS infections in newborn babies remains higher than before the risk-based prevention strategy was introduced in 2003, although it has fallen significantly in other countries which offer routine antenatal testing. Despite this, the UK National Screening Committee remained unconvinced this time, but we have not given up and will continue to increase awareness and press for change.

At a meeting with the Parliamentary Under Secretary of State, Department of Health, Dr Dan Poulter MP, and the Chief Medical Officer, Prof Dame Sally Davies in December 2012, it was agreed that steps would be taken to ensure health professionals will be able to access the ‘gold standard’ ECM (Enriched Culture Medium) tests for group B Strep carriage in NHS laboratories. This means the best tests will be available, improving prevention of these severe infections. We are delighted by this and look forward to it becoming a reality during 2013.

Jane Plumb MBE

Medical panel

Prof Philip Steer, Emeritus Professor at Imperial College and Consultant Obstetrician at the Chelsea and Westminster Hospital, London

Dr Alison Bedford-Russell MRCP Clinical Director for Neonatology at Birmingham Women’s NHS Foundation Trust and West Midlands Strategic Clinical Network Clinical Director for Maternity & Newborn, Birmingham

Philippa Cox, Consultant Midwife/Supervisor of Midwives, Homerton University Hospital NHS Foundation Trust, London

Dr Christine McCartney OBE, FRCPath Senior Adviser on Microbiology Services to CEO, Public Health England, London

Dr Chris Steele MBE, resident doctor on ITV’s This Morning, is Group B Strep Support’s Patron. Known and trusted by millions, family GP Dr Steele is renowned for his practical and open approach to airing medical issues in the media. www.drchrissteele.com

Jane Plumb MBE, chief executive of Group B Strep Support
Every year, large numbers of babies are affected by life threatening group B Streptococcal infection. Whilst most recover, some are stillborn, more die in the first weeks of life and others suffer lifelong disability.

Group B Strep, known as GBS or Strep B, is Britain’s most frequent cause of severe early-onset (0–6 days of life) infection in babies. Most GBS infection in babies is early onset and these infections are highly preventable.

Prevention methods are not currently available for late-onset (after age 6 days) GBS infection and this report therefore focuses on those of early onset only.

A simple maternal GBS screening programme could identify women carrying the potentially lethal bacteria and those women, and others known to be at higher risk, could be offered antibiotics in labour to minimise the risk of GBS infection in their newborn babies. Many countries have already recognised the scale of the problem, and have introduced screening programmes, including Australia, Argentina, Belgium, Canada, Chile, Czech Republic, France, Germany, Hong Kong, Italy, Japan, Kenya, Lithuania, Oman, Poland, Spain, Slovenia, Switzerland and the USA.

As a result of these screening programmes, the number of GBS infections in newborn babies has fallen significantly – in the USA by over 80%, in Spain by 86%, in Australia by 82% and in France by 71%. In the UK, routine screening for GBS is not offered and the incidence has increased (see graphs).

Since 2003, the number of voluntarily reported culture-proven GBS infections in newborn babies has risen by 23% to 281 cases in England, Wales and Northern Ireland in 2011. Even with the best medical care, about one in ten babies with GBS infection die and, although most survivors recover fully, up to half of those who recover from GBS menigitis suffer long-term problems. If current trends continue, the number of GBS infections and resultant deaths and disabilities among newborn babies will double within the next three decades.

Many obstetricians, paediatricians and midwives are concerned that Britain is out of sync with much of the rest of the developed world. Approximately one in four people in Britain are likely carriers of the GBS bacteria, which produces no symptoms – the first many parents realise that they are carriers of the GBS bacteria is when their baby is fighting for its life in the Special Care Baby Unit.

Within the last six years, four reports[6-11] have been commissioned through the Government’s Health Technology Assessment Programme, the Medical Research Council and other healthcare research agencies, to establish how to combat preventable GBS infection in newborn babies. All have found screening to be more cost effective

[Graphs and tables are omitted for this text]

Lab reports of early onset (0-6 day) GBS bacteremia in infants: England & Wales 2000-2011

Incidence of early- and late-onset invasive group B streptococcal (GBS) disease: Active Bacterial Core surveillance areas, 1990–2008, and activities for prevention of GBS disease

GBS is the most common cause of life-threatening infection in newborn babies, causing death and disability

• GBS infections in newborn babies continue to rise in the United Kingdom
• GBS infections in newborn babies have fallen substantially in countries which routinely screen

Group B Strep Support continues to make the case for improved prevention and would like to see

• Sensitive GBS testing offered by the NHS to all pregnant women
• All pregnant women given information about GBS as part of routine antenatal care
• Intravenous antibiotics offered during labour to all women with identified risk factors (including GBS carriage detected by testing)
• All appropriate health professionals to be fully informed about group B Strep - the availability of ECM testing for GBS carriage, how and when these tests should be administered and what prevention strategies are available
Mikey Walsh was born on 3 April 2008 in Wakefield. “From twelve hours old, I could tell something was not quite right,” says his mum, Natasha. She raised concerns with several health professionals, but they were fairly dismissive. At three days, she had had enough and took Mikey to see a community midwife. Mikey had lost weight and was hypothermic. After a lumbar puncture was taken, his parents were told it was meningitis. He subsequently stopped breathing five times and had to be revived. He was rushed to Intensive Care where Mikey’s parents were told he might not make it through the right and that there was a good chance of brain damage. He survived the night but three weeks later the brain damage was confirmed.

“The first twelve months were very hard for us as a family,” says Natasha, “Mikey was having up to six fits a day, he never slept and our family was under immense pressure. We were exhausted.”

For the next couple of years, Mikey thrived and appeared to hit every milestone, though not always in the correct order or at the correct time. “We were thinking we had got through this unscathed. But Mikey was falling over a lot, he seemed to run with his right foot on his tip-toes and he carried his right arm awkwardly. He talked loads, but some words were quite hard to understand.”

“Our consultant told us that Mikey had cerebral palsy affecting the right hand side of his body. We were devastated.”

“What has given us hope is Mikey himself. He beat group B Streptococcus as a newborn and he thinks he was put on this earth to entertain everybody and make people smile. Mikey leads a normal and full life like any five year old. He overcomes any obstacles put in front of him, with the help of physio and speech therapy.”

What is group B Streptococcus?

Group B Streptococcus is a bacterium carried harmlessly in the vagina of approximately 21% of pregnant women in the UK.15

It usually only becomes a problem if a baby is exposed to it around the time of labour as the immune systems of newborn infants are less able to fight off its potentially damaging effects. If GBS gets into the bloodstream or lungs of a newborn baby, it can cause septicaemia and pneumonia, each of which can be fatal and is expensive to treat. Most GBS infections in babies develop within the first hours and days of life but, less commonly, it can develop up to age three months. Then it is more likely to cause meningitis, which can be fatal or cause a range of lifelong disabilities including blindness, deafness, speech problems or learning impairments.

It is not clear how many babies’ deaths and disabilities from group B Strept infections are excluded from official statistics because babies are rapidly treated on symptoms alone before a diagnosis is made, or because a baby is stillborn due to GBS infection and the cause of the infection is never investigated.

In the UK, anything up to 88,000 babies a year are colonised with GBS at birth. In 2003, it was estimated that 340 babies11 a year in the UK developed GBS infection aged 0–6 days, with varying degrees of severity and 39 died from their infection, although subsequent research shows that the true current incidence could be three times greater12. A study in a major London hospital found an incidence of proven GBS infection of 1.1 per 1,000 live births, but this increased to 3.6 per 1,000 live births when it included probable cases - one case in every 277 babies born1. UK wide, this would mean around 2,500 newborn babies requiring treatment, even though many may never be formally identified as infected with GBS.

In the UK as a whole, about one in seven of all newborn babies requires some extra hospital care, which can cost £1,200 or more a day depending on how much intensive nursing they need. Removing the GBS cases would not only save money but also free up many intensive care cots for other sick babies.

What is group B Streptococcus? Group B Streptococcus is a bacterium carried harmlessly in the vagina of approximately 21% of pregnant women in the UK15. It usually only becomes a problem if a baby is exposed to it around the time of labour as the immune systems of newborn infants are less able to fight off its potentially damaging effects. If GBS gets into the bloodstream or lungs of a newborn baby, it can cause septicaemia and pneumonia, each of which can be fatal and is expensive to treat. Most GBS infections in babies develop within the first hours and days of life but, less commonly, it can develop up to age three months. Then it is more likely to cause meningitis, which can be fatal or cause a range of lifelong disabilities including blindness, deafness, speech problems or learning impairments.

When does group B Streptococcus infection occur in babies? Group B Streptococcus infection can occur at any point from the first trimester of pregnancy to the neonatal period. However, the majority of cases occur in the neonatal period, with the highest incidence in the first 24 hours of life. While the cause of death in infants is directly attributable to GBS, the infection may also cause other disabilities such as cerebral palsy, hearing loss, and meningitis.

How is group B Streptococcus infection diagnosed? Group B Streptococcus infection is diagnosed through a blood test, urine test, or swab of the newborn’s rectum or throat. Antibiotics are given to the newborn to prevent further complications. Newborns may also be given antibiotics through a lumbar puncture to prevent meningitis.

What are the risks of group B Streptococcus infection? Group B Streptococcus infection can have serious consequences for newborns, including brain damage, hearing loss, and meningitis. If meningitis occurs, it can be fatal or cause lifelong disabilities such as cerebral palsy. The infection can also cause stillbirth.

What can be done to prevent group B Streptococcus infection? Preventing group B Streptococcus infection in newborns involves identifying carriers of the bacteria. This is done through testing pregnant women for GBS at 35–37 weeks of pregnancy. If a woman is a carrier, she is given antibiotics to prevent the bacteria from passing to the newborn. This helps to reduce the risk of infections and complications in newborns.
had health professionals followed existing guidelines to give antibiotics when risk factors were identified. Of the women with recognised risk factors, only six (21%) received the correct antibiotics during labour. Four more mothers were prescribed the wrong antibiotics. Recent studies from other countries have shown no risk factors to be present in even higher proportions of newborn babies developing GBS infection (57% to 78%)1,2.

There is little evidence that the guidelines have brought about more recent improvements. “I have seen cases where senior doctors have used completely the wrong antibiotics, and haven’t even thought of screening women for the infection,” said Alison Bedford Russell, a senior consultant neonatologist at Birmingham Women’s Hospital, who regularly has to treat tiny babies with undiagnosed GBS infection, fighting for their lives. “The UK is now very much behind the rest of the world on this.”

Whilst there are real concerns about using antibiotics inappropriately and promoting antibiotic resistance by over-use, studies in the US have shown these fears have not been realised except when broad spectrum,3 rather than the recommended narrow spectrum, antibiotics were used against GBS infection in newborn babies. Likewise, concerns about the antibiotics causing major allergic reactions, with potently devastating effects for both the mother and her baby, have largely been allayed.4

In July 2012, the Royal College of Obstetricians & Gynaecologists released their updated Green-top guideline on the prevention of early-onset group B Streptococcal disease (No 36)5. There are some minor improvements to the updated guideline, particularly in giving more clarity (for example, the guidelines now use the term ‘offer’ rather than ‘consider’ giving antibiotics in labour for women found to carry GBS during the current pregnancy). Disappointingly, they reiterate their previous recommendation for a risk-based prevention strategy, despite the lack of evidence that these have been effective. In August 2012, the National Institute for Health and Care Excellence (NICE) published a new guideline on the use of antibiotics for the prevention and treatment of early-onset (within 72 hours of birth) neonatal infection,21 including those caused by GBS. The guidelines, when implemented, will help ensure that antibiotics are used wisely and well for the prevention and treatment of bacterial infections in newborn babies.

Screening would be welcomed by expectant mothers

A survey in 2011 of 1,000 women aged 20–35 found that 92% would welcome the opportunity for pregnant women to be screened for group B Strept in the later stages of pregnancy and believe this should be offered to women routinely.

The case for screening

Many more cases of GBS infection in newborn babies can be prevented by routine screening (which identifies women actually carrying GBS) rather than using the current strategy of risk factors (many women have risk factors but don’t actually carry GBS), although the proportion of women offered antibiotics in labour would be similar.22 In addition, at least a third of newborn babies with GBS infection are born to mothers with no recognised risk factors.20,21

Risk-based programmes, because of their complexity, have a lower adherence than screening programmes. The evidence from countries which do screen shows dramatic falls in the incidence of GBS infection in newborn babies unlike in the UK.

Testing pregnant women for GBS carriage involves swabs being taken from the low vagina and rectum at 35–37 weeks of pregnancy and growing the bacteria using enriched culture techniques, which can take up to three days. The swabs can be taken by the pregnant woman herself, or by her health professionals, and there are no risks associated with the test. In countries which screen for GBS, mothers who go into labour before the test result is available are routinely offered antibiotics in labour based on risk factors, such as prematurity or fever in labour.

A 2007 Health Technology Assessment study commissioned by the Government estimated that £67m could be saved were GBS detection optimised.23 That figure is likely to be a huge under-estimate because of rising healthcare costs.

In 2010, health economists at the University of Birmingham published a study estimating that introducing universal GBS screening for pregnant mothers at 35–37 weeks of pregnancy would save £633,000 for every baby death avoided and £45,000 per disease avoided.24 There are insufficient data to assess the lifetime costs for babies left with disabilities, but these will be significant. Four recent UK reports10–12 have concluded that screening would be more cost effective than risk-based prevention.

Screening would be welcomed by expectant mothers

A survey in 2011 of 1,000 women aged 20–35 found that 92% would welcome the opportunity for pregnant women to be screened for group B Strept in the later stages of pregnancy and believe this should be offered to women routinely.

One week after being born, Owen was taken to hospital where he was reuscitated after being born with GBS.

Cameron. Over the following years, he offered his support for preventing other newborn babies from being infected with this devastating bacteria.

“The case for screening”

Screening would be welcomed by expectant mothers

A survey in 2011 of 1,000 women aged 20–35 found that 92% would welcome the opportunity for pregnant women to be screened for group B Strept in the later stages of pregnancy and believe this should be offered to women routinely.

The case for screening

Many more cases of GBS infection in newborn babies can be prevented by routine screening (which identifies women actually carrying GBS) rather than using the current strategy of risk factors (many women have risk factors but don’t actually carry GBS), although the proportion of women offered antibiotics in labour would be similar.22 In addition, at least a third of newborn babies with GBS infection are born to mothers with no recognised risk factors.20,21

Risk-based programmes, because of their complexity, have a lower adherence than screening programmes. The evidence from countries which do screen shows dramatic falls in the incidence of GBS infection in newborn babies unlike in the UK.

Testing pregnant women for GBS carriage involves swabs being taken from the low vagina and rectum at 35–37 weeks of pregnancy and growing the bacteria using enriched culture techniques, which can take up to three days. The swabs can be taken by the pregnant woman herself, or by her health professionals, and there are no risks associated with the test. In countries which screen for GBS, mothers who go into labour before the test result is available are routinely offered antibiotics in labour based on risk factors, such as prematurity or fever in labour.

A 2007 Health Technology Assessment study commissioned by the Government estimated that £67m could be saved were GBS detection optimised.23 That figure is likely to be a huge under-estimate because of rising healthcare costs.

In 2010, health economists at the University of Birmingham published a study estimating that introducing universal GBS screening for pregnant mothers at 35–37 weeks of pregnancy would save £633,000 for every baby death avoided and £45,000 per disease avoided.24 There are insufficient data to assess the lifetime costs for babies left with disabilities, but these will be significant. Four recent UK reports10–12 have concluded that screening would be more cost effective than risk-based prevention.

Screening would be welcomed by expectant mothers

A survey in 2011 of 1,000 women aged 20–35 found that 92% would welcome the opportunity for pregnant women to be screened for group B Strept in the later stages of pregnancy and believe this should be offered to women routinely.

The case for screening

Many more cases of GBS infection in newborn babies can be prevented by routine screening (which identifies women actually carrying GBS) rather than using the current strategy of risk factors (many women have risk factors but don’t actually carry GBS), although the proportion of women offered antibiotics in labour would be similar.22 In addition, at least a third of newborn babies with GBS infection are born to mothers with no recognised risk factors.20,21

Risk-based programmes, because of their complexity, have a lower adherence than screening programmes. The evidence from countries which do screen shows dramatic falls in the incidence of GBS infection in newborn babies unlike in the UK.

Testing pregnant women for GBS carriage involves swabs being taken from the low vagina and rectum at 35–37 weeks of pregnancy and growing the bacteria using enriched culture techniques, which can take up to three days. The swabs can be taken by the pregnant woman herself, or by her health professionals, and there are no risks associated with the test. In countries which screen for GBS, mothers who go into labour before the test result is available are routinely offered antibiotics in labour based on risk factors, such as prematurity or fever in labour.

A 2007 Health Technology Assessment study commissioned by the Government estimated that £67m could be saved were GBS detection optimised.23 That figure is likely to be a huge under-estimate because of rising healthcare costs.

In 2010, health economists at the University of Birmingham published a study estimating that introducing universal GBS screening for pregnant mothers at 35–37 weeks of pregnancy would save £633,000 for every baby death avoided and £45,000 per disease avoided.24 There are insufficient data to assess the lifetime costs for babies left with disabilities, but these will be significant. Four recent UK reports10–12 have concluded that screening would be more cost effective than risk-based prevention.

Screening would be welcomed by expectant mothers

A survey in 2011 of 1,000 women aged 20–35 found that 92% would welcome the opportunity for pregnant women to be screened for group B Strept in the later stages of pregnancy and believe this should be offered to women routinely.
In addition, 92% believe that information on group B Strep should be given to all pregnant women yet almost 50% of them had no idea what GBS is (and of those who had heard of it, only 20% knew what it was).

Furthermore, 95% believe antibiotics should be offered in labour to women with group B Strep and that they themselves would definitely, or probably, accept the offer (89%).

Sadly, all too often parents only find out when tragedy strikes.

Is more research needed?

More research is always welcome when it sheds light on something not understood. However, further research, if required before introducing screening, would mean more avoidable deaths occur while more and better evidence is collected for what is already known: screening strategies are better than risk factor strategies at preventing group B Strep infections in newborn babies.

There is a perception that health professionals just aren’t being given the tools they need to tackle these devastating infections and the failure to offer routine antenatal testing for GBS using safe and effective tests, estimated to cost just £10.63 each in 2009, underlines this. The reasons for this are unclear, particularly against a backdrop of other countries seeing 80% falls in their incidence of early onset GBS disease following the introduction of preventative measures whilst the incidence in the UK has risen.

The prospects for a vaccine

Although there are at least eight different subgroups (or serotypes) of GBS causing infection in the UK, a vaccine against three of them (III, Ia and V) could prevent about three of them (III, Ia and V) could prevent about 70% of cases.

It could prevent GBS infections not only in newborn babies, but also the less common late-onset (occurring seven or more days after birth) infections, which are not prevented by antibiotics in labour, as well as maternal infections.

Such a vaccine has been developed by the pharmaceutical company Novartis, and has been trialled on 320 pregnant and non-pregnant women aged 18 to 40, in South Africa. The trial is deemed to have been successful and data from the trial is being analysed to determine the optimum dose to produce an antibody response. Further large-scale trials in pregnant women will then be required before the product can be licensed, which could take a further three to five years, assuming all is well.

Rolling out an NHS vaccine programme could take a decade or more, so it is important that screening is introduced as soon as possible to save more babies suffering these severe infections and dying in the meantime.

Conclusion

It is well recognised that GBS is causing avoidable severe infections in newborn babies, causing death and disability and that the incidence is rising in the UK. The existing Royal College of Obstetricians & Gynaecologists’ guidelines, whilst a huge step forward in 2003, have been shown to have had little effect on the incidence of these devastating infections.

Ample evidence is available of the life-saving benefits of screening, from countries that are offering it. Evidence also suggests that this would save the NHS money.

In the light of this, GBSIS is calling for:

• All appropriate health professionals to be fully informed about group B Strep: the availability of ECM testing for GBS carriage, how and when these tests should be administered and what prevention strategies are available.
• Every pregnant woman to be given information about GBS as part of routine antenatal care
• Sensitive GBS testing to be offered freely on the NHS to every pregnant woman whose newborn baby is at low risk of developing GBS infection
• Intravenous antibiotics to be offered during labour to women with group B Strep and that they themselves would definitely, or probably, accept the offer (89%).

In the light of this, GBSIS is calling for:  

- All appropriate health professionals to be fully informed about group B Strep: the availability of ECM testing for GBS carriage, how and when these tests should be administered and what prevention strategies are available.
- Every pregnant woman to be given information about GBS as part of routine antenatal care
- Sensitive GBS testing to be offered freely on the NHS to every pregnant woman whose newborn baby is at low risk of developing GBS infection
- Intravenous antibiotics to be offered during labour to women with group B Strep and that they themselves would definitely, or probably, accept the offer (89%).

In the light of this, GBSIS is calling for:

- All appropriate health professionals to be fully informed about group B Strep: the availability of ECM testing for GBS carriage, how and when these tests should be administered and what prevention strategies are available.
- Every pregnant woman to be given information about GBS as part of routine antenatal care
- Sensitive GBS testing to be offered freely on the NHS to every pregnant woman whose newborn baby is at low risk of developing GBS infection
- Intravenous antibiotics to be offered during labour to women with group B Strep and that they themselves would definitely, or probably, accept the offer (89%).

In the light of this, GBSIS is calling for:

- All appropriate health professionals to be fully informed about group B Strep: the availability of ECM testing for GBS carriage, how and when these tests should be administered and what prevention strategies are available.
- Every pregnant woman to be given information about GBS as part of routine antenatal care
- Sensitive GBS testing to be offered freely on the NHS to every pregnant woman whose newborn baby is at low risk of developing GBS infection
- Intravenous antibiotics to be offered during labour to women with group B Strep and that they themselves would definitely, or probably, accept the offer (89%).

In the light of this, GBSIS is calling for:

- All appropriate health professionals to be fully informed about group B Strep: the availability of ECM testing for GBS carriage, how and when these tests should be administered and what prevention strategies are available.
- Every pregnant woman to be given information about GBS as part of routine antenatal care
- Sensitive GBS testing to be offered freely on the NHS to every pregnant woman whose newborn baby is at low risk of developing GBS infection
- Intravenous antibiotics to be offered during labour to women with group B Strep and that they themselves would definitely, or probably, accept the offer (89%).

In the light of this, GBSIS is calling for:

- All appropriate health professionals to be fully informed about group B Strep: the availability of ECM testing for GBS carriage, how and when these tests should be administered and what prevention strategies are available.
- Every pregnant woman to be given information about GBS as part of routine antenatal care
- Sensitive GBS testing to be offered freely on the NHS to every pregnant woman whose newborn baby is at low risk of developing GBS infection
- Intravenous antibiotics to be offered during labour to women with group B Strep and that they themselves would definitely, or probably, accept the offer (89%).

In the light of this, GBSIS is calling for:

- All appropriate health professionals to be fully informed about group B Strep: the availability of ECM testing for GBS carriage, how and when these tests should be administered and what prevention strategies are available.
- Every pregnant woman to be given information about GBS as part of routine antenatal care
- Sensitive GBS testing to be offered freely on the NHS to every pregnant woman whose newborn baby is at low risk of developing GBS infection
- Intravenous antibiotics to be offered during labour to women with group B Strep and that they themselves would definitely, or probably, accept the offer (89%).

In the light of this, GBSIS is calling for:

- All appropriate health professionals to be fully informed about group B Strep: the availability of ECM testing for GBS carriage, how and when these tests should be administered and what prevention strategies are available.
- Every pregnant woman to be given information about GBS as part of routine antenatal care
- Sensitive GBS testing to be offered freely on the NHS to every pregnant woman whose newborn baby is at low risk of developing GBS infection
- Intravenous antibiotics to be offered during labour to women with group B Strep and that they themselves would definitely, or probably, accept the offer (89%).